Number and rate* of newly reported cases of chronic Hepatitis B virus infection, by demographic characteristics — United States, 2021

Number and rate* of newly reported cases of chronic Hepatitis B virus infection, by demographic characteristics — United States, 2021
The number and rates of newly reported cases of chronic hepatitis B, by demographic characteristics (age, sex, race/ethnicity, urbanicity, and US Department of Health and Human Services region) during 2021. The first column lists the demographic characteristics. The second column provides the number of newly reported chronic hepatitis B cases, and the third column provides the rate of cases per 100,000 population for each demographic category during 2021.
Characteristics No. Rate*
Total§ 14,229 5.9
Age (Years)
0–19 191 0.3
20–29 1,322 4.2
30–39 3,469 10.8
40–49 3,301 11.3
50–59 2,801 9.1
≥60 3,136 5.4
Sex
Male 8,176 6.9
Female 6,039 5.0
Race/Ethnicity
American Indian/Alaska Native, non-Hispanic 54 2.6
Asian/Pacific Islander, non-Hispanic 3,075 27.0
Black, non-Hispanic 2,455 7.7
White, non-Hispanic 2,989 1.9
Hispanic 689 2.1
Urbanicity
Urban 13,057 6.4
Rural 1,119 3.1
HHS Region: Regional Office**
Region 1: Boston 383 4.3
Region 2: New York 2,589 8.9
Region 3: Philadelphia 1,989 6.5
Region 4: Atlanta 4,685 8.5
Region 5: Chicago 1,955 3.7
Region 6: Dallas 859 8.0
Region 7: Kansas City 519 3.6
Region 8: Denver 387 3.1
Region 9: San Francisco 288 2.8
Region 10: Seattle 575 3.9
Source: CDC, National Notifiable Diseases Surveillance System.
* Rates per 100,000 population.
† Reported confirmed cases. For the case definition, see Chronic Hepatitis B.
§ Numbers reported in each category may not add up to the total number of reported cases in a year due to cases with missing data or, in the case of race/ethnicity, cases categorized as “Other.”
¶ Urban-rural region was categorized according to the 2013 National Center for Health Statistics (NCHS) urban-rural classification scheme for counties and county-equivalent entities. Large central metro, large fringe metro, medium metro, and small metro counties were grouped as urban. Micropolitan and noncore counties were grouped as rural.
** US Department of Health and Human Services regions were categorized according to the grouping of states and US territories assigned under each of the 10 Health and Human Services regional offices. For the purposes of this report, regions with US territories (Region 2 and Region 9) contain data from states only.

During 2021, the rate of newly reported cases of chronic hepatitis B was highest among persons aged 30–39 and 40–49 years and accounted for 48% of all chronic hepatitis B cases reported during 2021. The highest rate of newly reported chronic hepatitis B cases occurred in males, urban areas (as defined by the National Center for Health Statistics), and among US Department of Health and Human Services Region 2 (New Jersey, New York).

Although the rate of reported acute hepatitis B was the lowest among non-Hispanic Asian/Pacific Islander (A/PI) persons (Figure 2.6), the rate of newly reported chronic hepatitis B was highest among non-Hispanic A/PI persons (27.0 cases per 100,000 population) and was over 14 times the rate among non-Hispanic White persons (1.9 cases per 100,000 population). Variations of disease rates by race or ethnicity may reflect systemic cultural, behavioral, environmental, and social factors, including structural racism.

Race and ethnicity information was only available for 10,210 (72%) cases of newly reported chronic hepatitis B. Because the majority of prevalent chronic hepatitis B virus infections in the United States are among persons who are non-US-born,1 differences in the rates of newly reported chronic hepatitis B by race and ethnicity are likely influenced by country of birth. However, country of birth is not routinely collected in the National Notifiable Diseases Surveillance System.

Hepatitis B Figures and Tables

Source:

  1. Patel EU, Thio CL, Boon D, et al. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011–2016. Clin Infect Dis 2019;69:709–12.